BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17172846)

  • 1. EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells.
    Garcia R; Franklin RA; McCubrey JA
    Cell Cycle; 2006 Dec; 5(23):2820-6. PubMed ID: 17172846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Wong EW; Chang F; Lehmann B; Terrian DM; Milella M; Tafuri A; Stivala F; Libra M; Basecke J; Evangelisti C; Martelli AM; Franklin RA
    Biochim Biophys Acta; 2007 Aug; 1773(8):1263-84. PubMed ID: 17126425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
    Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
    Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of EGF/ERBB1 in the transcriptional regulation of the prolactin receptor independent of estrogen and prolactin in breast cancer cells.
    Kavarthapu R; Dufau ML
    Oncotarget; 2016 Oct; 7(40):65602-65613. PubMed ID: 27564112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance induced by HBx in hepatoma cell line.
    Guan J; Chen XP; Zhu H; Luo SF; Cao B; Ding L
    World J Gastroenterol; 2004 Dec; 10(23):3522-7. PubMed ID: 15526378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell death of MCF-7 human breast cancer cells induced by EGFR activation in the absence of other growth factors.
    Garcia R; Franklin RA; McCubrey JA
    Cell Cycle; 2006 Aug; 5(16):1840-6. PubMed ID: 16861904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer resistance protein/ABCG2 is differentially regulated downstream of extracellular signal-regulated kinase.
    Imai Y; Ohmori K; Yasuda S; Wada M; Suzuki T; Fukuda K; Ueda Y
    Cancer Sci; 2009 Jun; 100(6):1118-27. PubMed ID: 19514121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A switch role of Src in the biphasic EGF signaling of ER-negative breast cancer cells.
    Zhang X; Meng J; Wang ZY
    PLoS One; 2012; 7(8):e41613. PubMed ID: 22927910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGF receptor is involved in WNT3a-mediated proliferation and motility of NIH3T3 cells via ERK pathway activation.
    Kim SE; Choi KY
    Cell Signal; 2007 Jul; 19(7):1554-64. PubMed ID: 17374561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP).
    Meyer zu Schwabedissen HE; Grube M; Dreisbach A; Jedlitschky G; Meissner K; Linnemann K; Fusch C; Ritter CA; Völker U; Kroemer HK
    Drug Metab Dispos; 2006 Apr; 34(4):524-33. PubMed ID: 16415123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line.
    Kim S; Choi JH; Lim HI; Lee SK; Kim WW; Cho S; Kim JS; Kim JH; Choe JH; Nam SJ; Lee JE; Yang JH
    Cell Signal; 2009 Jun; 21(6):892-8. PubMed ID: 19385051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
    Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y
    Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes.
    Kasper M; Schnidar H; Neill GW; Hanneder M; Klingler S; Blaas L; Schmid C; Hauser-Kronberger C; Regl G; Philpott MP; Aberger F
    Mol Cell Biol; 2006 Aug; 26(16):6283-98. PubMed ID: 16880536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.
    Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y
    Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational up-regulation of Aurora-A in EGFR-overexpressed cancer.
    Lai CH; Tseng JT; Lee YC; Chen YJ; Lee JC; Lin BW; Huang TC; Liu YW; Leu TH; Liu YW; Chen YP; Chang WC; Hung LY
    J Cell Mol Med; 2010 Jun; 14(6B):1520-31. PubMed ID: 19799648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
    Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen.
    Günthert AR; Gründker C; Olota A; Läsche J; Eicke N; Emons G
    Eur J Endocrinol; 2005 Oct; 153(4):613-25. PubMed ID: 16189183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line.
    Xiao Z; Ding N; Xiao G; Wang S; Wu Y; Tang L
    Anat Rec (Hoboken); 2012 Dec; 295(12):2122-8. PubMed ID: 22907845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase-2 (COX-2) negatively regulates expression of epidermal growth factor receptor and causes resistance to gefitinib in COX-2-overexpressing cancer cells.
    Kim YM; Park SY; Pyo H
    Mol Cancer Res; 2009 Aug; 7(8):1367-77. PubMed ID: 19671676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.